---
schema_version: "secwatch.filing_event.v1"
accession: "0001701478-26-000039"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-08-12T20:55:16+00:00"
generated_at: "2026-08-12T20:56:10.311836+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Azitra Q2 net loss widens to $3.3M; pauses ATR-12, advances ATR-COSF and ATR-04

## Summary
- Net loss $3.3M in Q2 2026 vs $2.9M in Q2 2025; G&A up to $2.1M from $1.5M.
- Cash and cash equivalents $6.7M as of June 30, 2026.
- ATR-COSF: positive preclinical repeat-dose delivery and anti-wrinkle data in ex vivo human skin; proof-of-concept cosmetic study planned Q3 2026.
- ATR-04: continuing Phase 1/2 enrollment (6 sites incl. MD Anderson); topline data from first cohort expected Q4 2026.
- ATR-12 Netherton syndrome Phase 1b enrollment paused for capital allocation discipline.

## SEC filing metadata
- accession: 0001701478-26-000039
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-08-12T20:55:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/0001701478-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztr-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701478-26-000039
- JSON: https://secwatch.observer/filing/0001701478-26-000039.json
- Plain text: https://secwatch.observer/filing/0001701478-26-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.